New injection SZ1003 tested in Last-Resort liver cancer patients
NCT ID NCT07201064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test the safety and tolerability of a new drug called SZ1003 in 12 adults with advanced hepatocellular carcinoma who have already tried and failed at least two standard treatments. Participants receive the drug by infusion every two weeks, and researchers will monitor for side effects and any signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SZ1003 injection
- What this could lead to
- If it works, this could point toward a new treatment option for advanced liver cancer patients who have run out of standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 12 people, focused on safety. It is too soon to know if SZ1003 will effectively shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Promising drug cocktail targets Hard-to-Treat liver cancer
- Virus therapy takes on liver cancer in major trial